Skip to ContentSkip to Navigation
founded in 1614  -  top 100 university
About us Practical matters How to find us dr. E. Ammatuna

Publications

Pharmacological boosting of azacitidine/venetoclax in acute myeloid leukemia

Ten-day decitabine vs “3+7” in patients with AML aged ≥60 years: long-term results of the randomized phase 3 EORTC trial AML21

ΔNp73 isoform defines a TP53-mutant-like poor-risk subgroup of acute myeloid leukemia

Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial

Beneficial effect of PTCy and a short duration of immune suppression on relapse risk in acute myeloid leukemia patients with pretransplant MRD

Clonal Progression and Leukemic Transformation of a TP53 Mutated Post-Polycythaemia Vera Myelofibrosis

Correction: Anti-CD3/CD7 immunoconjugate (T-Guard) for severe, steroid-refractory GVHD: final report of BMT CTN 2002

Diagnosis and Treatment of Polycythemia Vera

High mtDNA content identifies oxidative phosphorylation-driven acute myeloid leukemias and represents a therapeutic vulnerability

Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcome

Sustainable Development Goals

SDG 3 - Good Health and Well-beingSDG 7 - Affordable and Clean Energy

More information about the Sustainable Development Goals.